Filing Flows › Mereo BioPharma Group (MREO) › Stock forecast & fair value
Mereo BioPharma Group (MREO) stock forecast and price target
Mereo BioPharma Group (MREO) trades at $0.28. 5 analysts' median price target is $1.96 (+592%), from $0.99 to $3.03.
Mereo BioPharma Group's latest quarter
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MREO stock?
The median of 5 analysts' 12-month targets is $1.96, +592% from $0.28; the range is $0.99 to $3.03. The average rating is none.
Does Mereo BioPharma Group usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is MREO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.